TABLE FOR GRADING THE SEVERITY OF ADVERSE EVENTS
|
|
- Melissa Hunt
- 5 years ago
- Views:
Transcription
1 TABLE FOR GRADING THE SEVERITY OF ADVERSE EVENTS Green AEs managed by DTUs REMARK Red Patient referral to provincial hospitals for AE management Note: In the case of patients with events at grade of severity in yellow box, but healthcare professionals at the DTUs are not eligible for treatment can still transfer patients to provincial hospital. In the case of patients with more signs or symptoms occured simultaneously, the severity of events are determined by the highest level of severity of symptoms (see also SOPs in Annex 5). Patients with the event at grade 3 and 4 needs to be hospitalised. Estimating severity grade for parameters not identified in the grading table: Grade 1: Grade 2: Grade 3: Grade 4: :c requires medical or operative to prevent permanent impairment, persistent disability or death PARAMETER GRADE 1 GRADE 2 GRADE 3 GRADE 4 SYSTEMIC Acute systemic allergic reaction Chills Localized urticaria (wheals) with no medical CLINICAL Localized urticaria with medical OR Mild angioedema with no medical Generalized urticaria OR Angioedema with medical OR Symptomatic mild bronchospasm Acute anaphylaxis OR bronchospasm OR laryngeal edema Fatigue Malaise Incapacitating fatigue/ malaise symptoms causing Fever (nonaxillary) C C C > 40.5 C Unintentional weight loss SKIN DERMATOLOGICAL 5 9% loss in body weight from baseline 10 19% loss in body weight from baseline 20% loss in body weight from baseline OR Aggressive [e.g., tube feeding or total parenteral nutrition (TPN)]
2 Cutaneous reaction rash Pruritis Alopecia GASTROINTESTIL Localized macular rash Itching causing no or Thinning detectable by study participant (or by caregiver for young children and disabled adults) Diffuse macular, maculopapular, or morbilliform rash OR Target lesions Itching causing Thinning or patchy hair loss detectable by health care provider Diffuse macular, maculopapular, or morbilliform rash with vesicles or limited number of bullae OR Superficial ulcerations of mucous membrane limited to one site Itching causing Complete hair loss Extensive or generalized bullous lesions OR Stevens-Johnson syndrome OR Ulceration of mucous membrane involving two or more distinct mucosal sites OR Toxic epidermal necrolysis (TEN) Nausea Transient (< 24 hours) or intermittent nausea with oral intake Persistent nausea resulting in decreased oral intake for hours Persistent nausea resulting in oral intake for > 48 hours OR aggressive rehydration (eg. IV fluids) Hypotensive shock) Vomiting Transient or intermittent vomiting with no or oral intake Frequent episodes of vomiting with no or mild rehydration Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration (eg. IV fluids) Hypotensive shock) Diarrhea Transient or intermittent episodes of unformed stools OR increase of 3 stools over baseline per 24-hour period Persistent episodes of unformed to watery stools OR Increase of 4-6 stools over baseline per 24-hour period Bloody diarrhea OR increase of 7 stools per 24 hour period OR IV fluid replacement Hypotensive shock) Dysphagia/ Odynophagia Symptomatic but able to eat usual diet altered dietary intake without medical severely altered dietary intake with medical reduction in oral intake
3 Constipation Persistent constipation requiring regular use of dietary modifications, laxatives or enemas Obstipation with manual evacuation Obstruction) Anorexia Loss of appetite without decreased oral intake Loss of appetite associated with decreased oral intake without significant weight loss Loss of appetite associated with significant weight loss OR Aggressive (eg. Tube feeding or total parenteral nutrition) Gastrointestinal bleeding Mucositis/stomatitis No treatment other than folic acid supplements Erythema of the mucosa Endoscopy Patchy pseudomembranes or ulcerations Blood transfusion Confluent pseudomembranes or ulcerations OR Mucosal bleeding with minor trauma (e.g., hypovolemic shock Tissue necrosis OR Diffuse spontaneous mucosal bleeding OR (e.g., aspiration, choking) Pancreatitis N/A Symptomatic AND Hospitalization not Symptomatic AND Hospitalization (other than emergency room visit) (e.g., circulatory failure, hemorrhage, sepsis) CARDIOVASCULAR Prolongation of the QT interval. Cardiac arrhythmia (general) (By ECG or physical exam) NEUROLOGIC second second >0.5 second or 0.6 second (from baseline) Asymptomatic AND No Asymptomatic AND Non-urgent medical Symptomatic, nonlifethreatening AND Non-urgent medical arrhythmia (eg. torsade de pointers or ventricular rhythm disorders) arrhythmia OR Urgent
4 Headache Vertigo Insomnia Symptoms causing no or Vertigo causing no or Difficulty falling asleep, difficulty staying asleep or early wake up at mild level Vertigo causing Difficulty falling asleep, difficulty staying asleep or early wake up at moderate level Vertigo causing Difficulty falling asleep, difficulty staying asleep or early wake up at severe level OR Hospitalization (other than emergency room visit) OR Headache with significant impairment of alertness or other neurologic function Disabling vertigo perform basic selfcare N/A Cognitive and behavioral/attentional disturbance (including dementia and attention deficit disorder) Altered Mental Status (including confusion, dementia, memory impairment, lethargy and coma) Alteration in personalitybehavior or in mood (e.g., agitation, anxiety, depression, mania, psychosis) Suicide Disability causing OR Specialized resources not Changes causing Alteration causing Thinking of death without intension of suicide Disability causing OR Specialized resources on parttime basis Mild lethargy or somnolence causing Alteration causing Thinking of death and suicide with no plan or clear intension Disability causing OR Specialized resources on a fulltime basis Confusion, memory impairment, lethargy, or somnolence social & Alteration causing Intension of suicide with partial or complete plan but not yet take any action or hospitalization Disability causing OR Institutionalization Delirium OR obtundation, OR coma Behavior potentially harmful to self or others (e.g., suicidal and homicidal ideation or attempt, acute psychosis) OR Causing inability to perform basic selfcare Trying to suicide
5 Neuromuscular weakness (including myopathy & neuropathy) Neurosensory alteration (including paresthesia and painful neuropathy) Asymptomatic with decreased strength on exam OR Minimal muscle weakness causing no or Asymptomatic with sensory alteration on exam or paresthesia causing no or Muscle weakness causing greater than interference with Sensory alteration or paresthesia causing Muscle weakness social & Sensory alteration or paresthesia social & Disabling muscle weakness causing OR Respiratory muscle weakness impairing ventilation Disabling sensory alteration or paresthesia perform basic selfcare Seizure: (new onset) 1 3 seizures Seizures of any kind which are prolonged, repetitive (e.g., status epilepticus), or difficult to control (e.g., refractory epilepsy) Seizure: (known preexisting seizure disorder) RESPIRATORY Increased frequency of pre-existing seizures (nonrepetitive) without change in seizure character OR Infrequent breakthrough seizures while on stable medication in a previously controlled seizure disorder Change in seizure character from baseline either in duration or quality (e.g., severity or focality) Seizures of any kind which are prolonged, repetitive (e.g., status epilepticus), or difficult to control (e.g., refractory epilepsy) Dyspnea or respiratory distress Dyspnea on exertion with no or usual social and Dyspnea on exertion causing greater than interference with usual social and Dyspnea at rest social and Respiratory failure with ventilatory support OCULAR/VISUAL/AUDITIVE Visual changes (from Visual changes causing or Visual changes causing Visual changes Disabling visual loss.
6 baseline) no interference with usual social and. usual social and. social and. Tinnitus or no usual social and. usual social and. Auditive loss N/A No or auditive support ENDOCRINE/METABOLIC usual social and. or auditive support N/A Severe auditive loss in both ears (>80dB, 2kHz and greater; or >50dB on audiogram or voice identification <50%) Hypothyroidism Diabetes mellitus Gynecomastia MUSCULOSKELETAL Arthralgia INJECTION SITE REACTION Infraclinical hyperthyroidism. And abnormal test results Glucose under control. No treatment required. Detectable by patient or caregiver and causing or no interference with usual social and. Joint pain causing Symptomatic causing greater than interference with OR Thyroid suppression therapy Medication OR Modification of current medications to regain glucose control Visually bbvious and causing greater than interference with Joint pain causing OR Uncontrolled despite treatment modification Uncontrollable hyperglycaemia despite medication OR Diabetes uncontrolled despite treatment modification Disfuguring and treatment and inability to social and. Joint pain causing (e.g., myxedema coma) (e.g., ketoacidosis, hyperosmolar nonketotic coma) N/A Disabling joint pain perform basic selfcare Pain at injection site Mild, no limitation of movements. Pain inducing partial mobility impairment. Pain causing Pain causing
7 Erythaema, oedema, nodule (induration) at injection site Pruritis associated with injection LABORATORY HEMATOLOGY Hemoglobin (Hb), decreased (male) Hemoglobin (Hb), decreased (female) 2.5 x 5 cm (or cm 2 ) causing no or Itching localized to injection site AND Relieved spontaneously or with < 48 hours treatment g/dl g/dl WBC, decreased /mm x x 10 9 /L Platelets, decreased /mm x x 10 9 /L 5-10 cm (or cm 2 Itching beyond the injection site but not generalized OR Itching localized to injection site requiring 48 hours treatment g/dl g/dl /mm x x 10 9 /L /mm x x 10 9 /L >10 cm (or >100cm 2 ) or ulceration or superinfection or superficial phlebitis or cold abscess or symptoms causing Generalized itching social & g/dl g/dl /mm x x 10 9 /L /mm x x 10 9 /L or hospitalization (e.g., abscess, skin necrosis) < 7.0 g/dl < 4.34 < 6.5 g/dl < 4.03 < 1.000/mm 3 < x 10 9 /L < /mm 3 < x 10 9 /L BIOCHEMISTRY ALT (SGPT), increased 1,25-2,5 x ULN 2,5-5,0 x ULN 5,0 10,0 x ULN 10,0 x ULN AST (SGOT), increased 1,25-2,5 x ULN 2,5-5,0 x ULN 5,0 10,0 x ULN 10,0 x ULN Bilirubin TP, increased 1,1 1,6 x ULN 1,6 2,6 x ULN 2,6 5,0 x ULN 5,0 x ULN Bilirubin TT, increased N/A N/A > ULN > ULN with life threatenting symptoms of liver failure) Potassium, serum 3,0 3,4 meq/l 3,0 3,4 2,5 3,0 meq/l 2,5 3,0 2,0 2,5 meq/l 2,0 2,5 < 2,0 meq/l < 2,0 Magnesium, serum 1,2 1,4 meq/l 0,60 0,70 0,9 1,2 meq/l 0,45 0,60 0,6 0,9 meq/l 0,30 0,45 < 0,60 meq/l < 0,30 Calcium, serum, 7,8 8,4 mg/dl 7,0 7,8 mg/dl 6,1 7,0 mg/dl < 6,1 mg/dl
8 decreased 1,95 2,10 1,75 1,95 1,53 1,75 < 1,53 Creatinin, serum, 1,1 1,3 x ULN 1,3 1,8 x ULN 1,8 3,5 x ULN 3,5 x ULN increased Glucose, serum, increased after meal mg/dl 6,44 8, mg/dl 8,89 13, mg/dl 13,89 27,75 > 500 mg/dl > 27,75 Glucose, serum, increased before meal Glucose, serum, decreased mg/dl 6,11 6, mg/dl 3,05 3, mg/dl 6,95 13, mg/dl 2,22 3, mg/dl 13,89 27, mg/dl 1,67 2,22 > 500 mg/dl > 27,75 < 30 mg/dl < 1,67 Lipase, serum, increased 1,1 1,5 ULN 1,5 3,0 ULN 3,0 5,0 ULN 5,0 x ULN Amylase, serum, 1,1 1,5 ULN 1,5 3,0 ULN 3,0 5,0 ULN 5,0 x ULN increased Lactate, serum, increased < 2,0 x ULN without acidosis 2,0 x ULN without acidosis Acid uric, serum, increased 7,5 10 mg/dl 0,45 0, mg/dl 0,59 0,71 Increased lactate with ph < 7,3 without life threatenting 12,0 15,0 mg/dl 0,71 0,89 Increased lactate with ph < 7,3 with life threatenting 15,0 mg/dl 0,89
Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events
Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Version 2.1 March 2017 Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes
More informationAzathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS
Azathioprine toxicity criteria and severity descriptors for the listing of biological agents for rheumatoid arthritis on the PBS Only valid for adult patients Azathioprine must be at a dose of at least
More informationWHO (World Health Organization) Toxicity Criteria by Grade
WHO (World Health Organization) Toxicity Criteria by Grade 化學治療以 WHO Toxicity Criteria 為主放射治療有分急性與慢性副作用以 RTOG Toxicity Criteria 為主 WHO Toxicity Criteria Category Toxicity Grade0 Grade1 Grade2 Grade3 Grade4
More informationT: N: M: EORTC SYSTEMIC THERAPY CHECKLIST. Protocol number: SeqID. Copyright EORTC August 2007 COMPARATIVE PERFORMANCE STATUS TABLE
EORTC SYSTEMIC THERAPY CHECKLIST Copyright EORTC August 2007 (Stick the patient s identification label here) Protocol number: SeqID. T: N: M: WHO / ECOG 0 Normal activity. 1 Symptoms but ambulatory. 2
More informationINSTRUCTIONS: 1. Use codetable on page 1 for modifications / termination reasons
Radiation Therapy Oncology Group Phase III Head & Neck Cancer Treatment Summary Form AMENDED DATA YES INSTRUCTIONS: 1 Use codetable on page 1 for modifications / termination reasons SUMMARY OF SYSTEMIC
More informationINVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests
Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash
More informationMabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection
MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults
More informationNilotinib AEs (adverse events) in CML population:
Nilotinib AEs (adverse events) in CML population: The percentages below were taken from a randomized trial of nilotinib 300mg BID in newly diagnosed Ph+ CML patients (N=279) taken from the Tasigna 2017
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationBRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
More informationCalcium (Ca 2+ ) mg/dl
Quick Guide to Laboratory Values Use this handy cheat-sheet to help you monitor laboratory values related to fluid and electrolyte status. Remember, normal values may vary according to techniques used
More informationGLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE
GLOSSARY OF MEDICAL TERMS IN LAY LANGUAGE The CSM Working Group on Patient Information recognises that users may not be familiar with the terms used in patient information leaflets to describe unwanted
More informationChemotherapy must not be started unless the following drugs have been given:
BC Cancer Protocol Summary for Second-Line Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Cancer Using Weekly PACLitaxel and Ramucirumab Protocol Code: Tumour Group: Contact
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:
More informationAdams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS
Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS Your health is important to us! The test descriptions listed below are for educational purposes only. Laboratory test interpretation
More informationNursing Process Focus: Patients Receiving Dextran 40 (Gentran 40)
Assess for presence/history of hypovolemia, shock, venous thrombosis. Assess vital signs: Hypovolemic shock secondary to surgery, burns, hemorrhage, other serious condition PT and PTT abnormalities Venous
More informationJ. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health
J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health Patient Clinical Information Questionnaire 1.0 Date of Questionnaire Completion; / / 2.0 Patient Data 2.1 Name:
More informationMonitor patient s ability to self-administer insulin. (To evaluate safe administration of drug.)
Nursing Process Focus: Patients Receiving Regular Insulin (Humulin, Novolin) Assessment Prior to administration: Assess any patient allergies. Older forms of insulin are made from beef and pork and may
More informationTIP Paclitaxel, Ifosfamide and Cisplatin
Systemic Anti Cancer Treatment Protocol TIP Paclitaxel, Ifosfamide and Cisplatin PROTOCOL REF: MPHATIPGC (Version No: 1.0) Approved for use in: Second line treatment of germ cell tumours Dosage: Drug Dosage
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
More informationPatient Name: Date: Address: Primary Care Physician: Online Website On TV In print On the radio
927 W. Myrtle St. Boise, ID 83702 (208) 947-0100 NEW PATIENT INTAKE Patient Name: Date: Email Address: Primary Care Physician: How did you hear about AVT? (Please mark all that apply) Online Website On
More informationCase TWO. Vital Signs: Temperature 36.6degC BP 137/89 HR 110 SpO2 97% on Room Air
Mr N is a 64year old Chinese gentleman who is a heavy drinker, still actively drinking, and chronic smoker of >40pack year history. He has a past medical history significant for Hypertension, Hyperlipidemia,
More informationBC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine
BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine Protocol Code Tumour Group Contact Physician UGOOVBEVV Gynecologic Oncology Dr.
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationPatient Name Date of Birth Page 1 of 6
2545 W. Hillcrest Dr. #205 Thousand Oaks, CA 91320 Admissions: 888.822.8938 Fax: 805.273.5246 Dear Medical Professional, This patient is seeking care to address eating disorder behaviors. For the patient
More informationBIOCHEMICAL REPORT. Parameters Unit Finding Normal Value. Lipase U/L Amylase U/L
Lipase U/L 88.9 10-195 Amylase U/L 1181.1 371.3-1192.6 West Delhi :- 7/148, Opp. MCD Office, Major Pankaj Batra Marg, Near Ramesh Nagar, New Delhi-15, Ph. : 011-47562566,9999830187 Liver Function Test
More informationMedication is just part of the management of these illnesses. Other therapies are also helpful; you may wish to discuss these with your prescriber.
Know Your Medicines Duloxetine The purpose of this leaflet is to give you some general information on duloxetine, and is intended as a guide only. This should be read in conjunction with the official patient
More informationNew Patient History. Name: DOB: Sex: Date: If yes, give the name of the physician who did your evaluation or ordered your tests:
New Patient History Name: DOB: Sex: Date: Chief Complaint: 1. Give a brief description of the problem you are seeking treatment for today: 2. Have you been evaluated for this problem or had any tests for
More informationBC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel
BC Cancer Protocol for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel Protocol Code Tumour Group Contact Physician UGOOVBEVP Gynecologic Oncology Dr. Anna Tinker
More informationCCRN Review - Renal. CCRN Review - Renal 10/16/2014. CCRN Review Renal. Sodium Critical Value < 120 meq/l > 160 meq/l
CCRN Review Renal Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC, CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Sodium 136-145 Critical Value < 120 meq/l > 160 meq/l Sodium Etiology
More informationBRAVTRAD. Protocol Code: Breast. Tumour Group: Dr. Susan Ellard. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN) and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour Group: Contact
More informationDIVISION OF CARDIOLOGY
Name: Date of Birth: / / Home Phone #: Cell Phone #: Work Phone #: Fax #: Address: City: State: Zip: Primary Care Physician: Office Address: Work #: Fax #: Referring Physician (if different): Office Address:
More informationDiscussing TECENTRIQ (atezolizumab) with your healthcare team
Discussing TECENTRIQ (atezolizumab) with your healthcare team What is TECENTRIQ? TECENTRIQ is a prescription medicine used to treat: a type of lung cancer called non-small cell lung cancer (NSCLC). TECENTRIQ
More informationTable of Contents. Course CME Credits. General Principles Topic CME Credit(s)
Table of Contents Course Course CME Credits Med-Challenger SPEX Comprehensive Review 266.0 CME Credits General Principles 21.0 CME Credit(s) Abdominal Pain 1.0 Acute Pelvic Pain in Women 1.0 Acute Vaginal
More informationAntiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA)
BC Cancer Protocol Summary for First Line Treatment of Locally Advanced Metastatic Pancreatic Cancer with Gemcitabine Protocol Code Tumour Group Contact Physician GIPGEMABR Gastrointestinal GI Systemic
More informationChapter 28. Media Directory. Hematopoiesis. Regulation of Hematopoiesis. Erythropoietin. Drugs for Hematopoietic Disorders
Chapter 28 Drugs for Hematopoietic Disorders Slide 35 Media Directory Epoetin Alfa Animation Upper Saddle River, New Jersey 07458 All rights reserved. Hematopoiesis Figure 28.1 Hematopoiesis Process of
More informationNivolumab. Other Names: Opdivo. About this Drug. Possible Side Effects (More Common) Warnings and Precautions
Nivolumab Other Names: Opdivo About this Drug Nivolumab is used to treat cancer. It is given in the vein (IV). Possible Side Effects (More Common) Bone marrow depression. This is a decrease in the number
More informationPlease list any treatments you have previously had for current illness. (Physical Therapy, Surgery, Radiation, etc.)
Date: Patient Name: D.O.B Last First M.I History of Present Illness: What is the reason for your visit? Date symptom started? Please list any treatments you have previously had for current illness. (Physical
More informationPlease describe, in detail, when the symptoms began:
161 East Mallard Drive, Suite 130, Boise, ID 83706 (208) 947-0100 New Patient Intake Patient Name: Primary Care Physician: Date: Email address: How did you hear about AVT (mark all that apply) Online On
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29
Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive
More informationExample Clinician Educational Material for Providers of Immune Effector Cellular Therapy
Example Clinician Educational Material for Providers of Immune Effector Cellular Therapy Disclaimer: This example is just one of many potential examples of clinician education material that can be provided
More informationNURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet)
NURSING PROCESS FOCUS: Patients Receiving Amphotericin B (Fungizone, Abelcet) ASSESSMENT Prior to administration: Obtain complete health history including allergies, drug history, and possible drug interactions.
More informationNSABP PROTOCOL B-34. Date Opened to Randomization: December 1, 2000 Date Closed to Randomization: March 31, 2004 Number of Patients Randomized: 3,323
NSABP PROTOCOL B-34 A Clinical Trial Comparing Adjuvant Clodronate Therapy versus Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy Date Opened
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine Protocol Code Tumour Group Contact Physician UBRAVTCAP Breast Dr. Stephen Chia ELIGIBILITY:
More informationNEW PATIENT VISIT QUESTIONNAIRE
HeartHealth A Program of the Dalio Institute of Cardiovascular Imaging NEW PATIENT VISIT QUESTIONNAIRE Name: Date of Birth: / / Address: City: State: Zip: Home Phone #: Work Phone #: Cell #: Email: Preferred
More informationWithout Background for printing as Pocket Reference
Without Background for printing as Pocket Reference Diabetes Prevention Program 1 LOOK AHEAD 3 Multi-center trial in patients with impaired glucose tolerance Weight loss of 7% reduced the rate of progression
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationDurvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study
Durvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study PLAnning Treatment For Oesophago-gastric cancer: a Randomised Maintenance therapy trial. ***See Protocol for further details***
More informationCisplatin / Paclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual
More informationPatient Treatment Date/time: Diagnosis: Treatment Regimen:
Name: Address: DOB: HCRN: Consultant: Ward: Assessment: Pre Systematic Anti Cancer Therapy (SACT) Continuation *This assessment is for patients on multiday regimens Patient Treatment Date/time: Diagnosis:
More informationBridges Family Wellness PC. New Patient Intake. Bridges Family Wellness Intake Form SE Lake Rd, Suite 102 Milwaukie, OR
New Patient Intake Bridges Family Wellness Intake Form Full Name: * What is your birthdate? MM/DD/YYYY * What is your gender identity? * Home address: * Cell Phone * Other Phone number(s): Emergency Contact
More informationHematopoiesis, The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid.
Hematopoiesis, 200 billion new blood cells per day The hematopoietic machinery requires a constant supply iron, vitamin B 12, and folic acid. hematopoietic growth factors, proteins that regulate the proliferation
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
More informationNPAC(W)+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIMACS FORM 07b: MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL, Version
IMACS FORM 07b: MYOSITIS ASSESSMENT TOOL, Version 2 2005 Subject s IMACS number: ASSESSOR: Date Assessed: Assessment number: The clinical features recorded are based upon the previous 4 weeks and the judgment
More informationCaspian Acupuncture -- Health History Form Anita Tayyebi EAMP, LAc. 652 SW 150 th St Burien WA 98166
Frist Name Last: Date Phone (H) (C) (W) E-mail Address City State Zip Age DOB Place of Birth _ Marital/Partnership Status Preferred Gender Pronoun _ Profession Family Physician Telephone # Referred By
More informationDiabetic Ketoacidosis
Diabetic Ketoacidosis Definition: Diabetic Ketoacidosis is one of the most serious acute complications of diabetes. It s more common in young patients with type 1 diabetes mellitus. It s usually characterized
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationOverview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs)
Overview of the MedDRA Data Retrieval and Presentation: Points to Consider Document including Standardised MedDRA Queries (SMQs) Judy Harrison Chief Medical Officer MedDRA MSSO 22 October 2013 MedDRA Data
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More informationMEDICATION GUIDE. Quetiapine (kwe-tye-a-peen) Tablets USP
MEDICATION GUIDE Quetiapine (kwe-tye-a-peen) Tablets USP Read this Medication Guide before you start taking quetiapine tablets and each time you get a refill. There may be new information. This information
More informationPRODUCT MONOGRAPH GEMCITABINE INJECTION
PRODUCT MONOGRAPH Pr GEMCITABINE INJECTION Concentrate Sterile Solution for Injection Gemcitabine (as Gemcitabine Hydrochloride) 40 mg gemcitabine per ml 200 mg/5 ml, 1 g/25 ml, 2 g/50 ml Antineoplastic
More informationInner Balance Acupuncture
Patient Information Inner Balance Acupuncture 274 Southland Drive, Suite 101, Lexington, KY 40503 859-595-2164 www.acupunctureky.com Name: Today s date: Age: Male Female Marital status: Date of Birth:
More informationDocumentation Dissection
History of Present Illness: Documentation Dissection The patient is a 50-year-old male c/o symptoms for past 4 months 1, severe 2 bloating and stomach cramps, some nausea, vomiting, diarrhea. In last 3
More informationMEDICATION GUIDE Mefloquine Hydrochloride Tablets, USP
Important: Your doctor or pharmacist will give you an Information Wallet Card along with this Medication Guide. It has important information about mefloquine and should be carried with you at all times
More informationDOSING GUIDE. Indications. Important Safety Information. Enable the immune system. RECOGNIZE. RESPOND.
DOSING GUIDE For patients with unresectable Stage III NSCLC following concurrent CRT For patients with locally advanced or metastatic UC previously treated with platinum-based therapy Enable the immune
More informationPRODUCT MONOGRAPH. Ready-to use solution. 38 mg/ml gemcitabine (as gemcitabine hydrochloride) 200 mg / 5.3 ml, 1 g / 26.3 ml, and 2 g / 52.
PRODUCT MONOGRAPH Pr GEMCITABINE INJECTION Ready-to use solution 38 mg/ml gemcitabine (as gemcitabine hydrochloride) 200 mg / 5.3 ml, 1 g / 26.3 ml, and 2 g / 52.6 ml Sterile THERAPEUTIC CLASSIFICATION
More informationUNDERSTANDING HAIR THINNING/HAIR LOSS
UNDERSTANDING HAIR THINNING/HAIR LOSS INDICATION AUBAGIO (teriflunomide) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. IMPORTANT SAFETY INFORMATION WARNING: HEPATOTOXICITY
More informationJune 2009 Respiratory Committee CALGB 30610
30610 Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide Activated: March 15, 2008 Study Chairpersons: J. Bogart
More informationSupplement Table 1. Definitions for Causes of Death
Supplement Table 1. Definitions for Causes of Death 3. Cause of Death: To record the primary cause of death. Record only one answer. Classify cause of death as one of the following: 3.1 Cardiac: Death
More informationChange in Condition: When to report to the MD/NP/PA
Change in Condition: When to report to the MD/NP/PA Immediate Notification Any symptom, sign or apparent discomfort that is: Acute or Sudden in onset, and: A Marked Change (i.e. more severe) in relation
More informationSick Call Screener Course
Sick Call Screener Course SOAP Note (1.3) 1.3-2-1 Enabling Objective 1.5 Document a patient encounter 1.3-2-2 SOAP Note Standard for documentation Designed to allow easy reference for follow-up care. (U.S.
More informationCECILIA P MARGRET MD PhD MPH Child, Adolescent and Adult Psychiatry NE 24th ST Suite 104, Bellevue WA 98007, Phone / Fax: +1 (425)
IDENTIFYING INFORMATION PATIENT INFORMATION FORM Patient's Name: DOB: Ethnicity/race: Gender: Primary language if other than English: Address: Phone: Home/ Mobile/ Work Email: Occupation: Marital Status:
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationTransfusion Reactions
Transfusion Reactions From A to T Provincial Blood Coordinating Program Daphne Osborne MN PANC (C) RN We want you to know Definition Appropriate actions Classification Complete case studies Transfusion
More informationCase Series Drug Analysis Print Name: Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine 01Sep Oct2014
- 16Oct2014 Report Run Date: 20-Oct-2014 Data Lock Date: 16-Oct-2014 19:00:06 Earliest Reaction Date: 28-Oct-2009 MedDRA Version: MedDRA 17.0 Vaxigrip, Fluarix, Inflexal V og Influenzacvaccine : Alle cases
More informationI. ALL CLAIMS: HEALTH CARE PROFESSIONALS
HCP Prescribing Information Date/Version January 2015 Version 2 Page: 1 of 5 I. ALL CLAIMS: HEALTH CARE PROFESSIONALS Indications and Usage Saxenda (liraglutide [rdna origin] injection) is indicated as
More informationT- Timing- concise vs. complete and thorough, depending on need of presenter and audience. E- Elicit- ask for feedback- more information needed? Less?
Review of STAGE presentation framework (from umass.macy.edu, revised Alicia Monroe, MD from 2005 STFM) S- style organization, sequencing adequate to build a case for your diagnosis or a story T- Timing-
More informationSkills: Recall the incidence of seizures Recall the causes of seizures Describe types of seizures List signs and symptoms of seizure patients
Medical 1 Resuscitation Describe the morbidity and mortality associated with sudden cardiac arrest List the chain of survival for sudden cardiac arrest as identified by the American Heart Association Discuss
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Yes No Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: Yes No If YES, please list medication allergies:
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More informationPATIENT HEALTH QUESTIONNAIRE Radiation Oncology
REVIEWED DATE / INITIALS Safety: Are you at risk for falls? Do you have a Pacemaker? Females; Is there a possibility you may be pregnant? Allergies: If YES, please list medication allergies: Do you have
More informationBroward Oncology Associates, P.A. PATIENT INFORMATION
NAME: BIRTHDATE: AGE: LOCAL ADDRESS (Street city state zip): HOME TELEPHONE# CELL # SOCIAL SECURITY #: - - SEX MARITAL STATUS WHAT IS YOUR HT? WHAT IS YOUR WT? EMPLOYER WORK# SPOUSE'S NAME SPOUSE'S EMPLOYER
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER 250 mg film-coated tablets. 500 mg film-coated tablets. 750 mg film-coated tablets. 1000 mg film-coated tablets. Levetiracetam
More information*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events.
Assessment Prior to administration: Obtain complete health history including allergies, drug history, and possible drug reactions Assess reason for drug administration such as presence/history of anemia
More informationSupplementary materials
Supplementary materials Table S Adverse events identified by participants diary logs and blood hematologic and biochemical tests (n=2) group (n=) Placebo group (n=) P value for chi-squared test Asthma
More informationPLACE LABEL HERE. Radiation Therapy Oncology Group Phase II Nasopharyngeal Cancer Follow-Up Form
F1 AMENDED DATA Radiation Therapy Oncology Group Phase II Nasopharyngeal Cancer Follow-Up Form YES No INSTRUCTIONS: Submit this form at the appropriate follow-up interval and at death Dates are recorded
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More informationPRODUCT MONOGRAPH. FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION. Anti-inflammatory, Analgesic
0 PRODUCT MONOGRAPH FLOCTAFENINE Floctafenine Tablets 200 mg and 400 mg THERAPEUTIC CLASSIFICATION Anti-inflammatory, Analgesic INFORMATION FOR THE PATIENT FLOCTAFENINE, which has been prescribed to you
More informationBlood/Blood Component Utilization and Administration Annual Compliance Education
Blood/Blood Component Utilization and Administration Annual Compliance Education This course contains annual compliance education necessary to meet compliance and regulatory requirements. Instructions:
More informationPRODUCT MONOGRAPH. Gemcitabine for Injection. 200 mg, 1 g and 2 g gemcitabine (as gemcitabine hydrochloride) per vial House Std. Antineoplastic Agent
PRODUCT MONOGRAPH Pr Gemcitabine for Injection 200 mg, 1 g and 2 g gemcitabine (as gemcitabine hydrochloride) per vial House Std. Antineoplastic Agent Accord Healthcare Inc. 3100, Steels Avenue East, Markham,
More informationGASTROENTEROLOGY PATIENT QUESTIONNAIRE - PLEASE PRINT
GASTROENTEROLOGY PATIENT QUESTIONNAIRE - PLEASE PRINT Full name: Date: Telephone Number: Age: Address: Email address: CHIEF COMPLAINTS(List the problems about which you came to see the doctor) 1) 2) 3)
More informationBC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine
BC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAJCAP Breast Dr. Stephen Chia ELIGIBILITY: Adjuvant breast cancer therapy
More informationEXCLUSIONS: Suspected dihydropyrimidine dehydrogenase (DPD) deficiency (see Precautions)
BC Cancer Protocol Summary for Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion and Leucovorin Infusion Protocol Code: Tumour Group: Contact
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) Date of FAR:
Core Safety Profile Active substance: Doxazosin Pharmaceutical form(s)/strength: Immediate release tablets 1 mg, 2 mg, 4 mg and 8 mg (IR) P - RMS: DK/H/PSUR/0004/002 Date of FAR: 12.12.2011 4.3 Contraindications
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More information